ReviewCancers2021
Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.Prostate cancer and prostatic diseases · 2026Trial
- Hugo™ RAS for robot-assisted radical prostatectomy: outcomes from a consecutive single-center study at a Hugo-exclusive institution.Journal of robotic surgery · 2026Article
- Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis.Clinical and translational radiation oncology · 2026Article
- Predictors of persistent PSA after robot-assisted radical prostatectomy: a high-volume single-center experience.Journal of robotic surgery · 2026Article
- Article
- PSMA-PET/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy.World journal of urology · 2025Article
- Radiomics Features from Different Prostatic Zones onCancers · 2025Article
- Multimodal radiomics based on fluorine-18 prostate-specific membrane antigen positron emission tomography and multiparametric magnetic resonance imaging in predicting persistent prostate-specific antigen after radical prostatectomy.Quantitative imaging in medicine and surgery · 2025Article
- Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.Abdominal radiology (New York) · 2025Review
- A machine learning model incorporatingQuantitative imaging in medicine and surgery · 2025Article
- Comparison betweenAsian journal of urology · 2025Article
- Article
- Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy.Diagnostics (Basel, Switzerland) · 2024Article
- A dynamic online nomogram predicting prostate cancer short-term prognosis based onAbdominal radiology (New York) · 2024Article
- Analysis of risk factors for persistent PSA after radical prostatectomy: results from a high-volume center in Southeast China.BMC urology · 2024Article
- Cribriform pattern 4/intraductal carcinoma of the prostate and persistent prostate-specific antigen after radical prostatectomy.BJUI compass · 2024Article
- Analysis of risk factors for disease progression after salvage radiation therapy with androgen deprivation therapy in prostate cancer patients who have prostate-specific antigen persistence after radical prostatectomy.Radiation oncology journal · 2024Article
- Review
- Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis.Asian journal of urology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a systematic review and meta-analysis to assess the prognostic value of prostate-specific antigen (PSA) persistence 4-8 weeks after radical prostatectomy (RP) in patients with prostate cancer, using studies from Medline, Scopus, and Cochrane Library, on 10 October 2020. Studies were eligible if they compared patients with postoperative PSA persistence 4-8 weeks after RP to those without such persistence to assess the value of PSA persistence in prognosticating biochemical recurrence (BCR), disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM) by multivariable analysis. Our review and analysis included nine studies published between 2008 and 2019 with 14,455 patients. Of those studies, 12.0% showed postoperative PSA persistence. PSA persistence was associated with BCR (HR: 4.44, 95% CI: 2.84-6.93), disease recurrence (HR: 3.43, 95% CI: 1.62-7.25), and CSM (HR: 2.32, 95% CI: 1.83-2.95). We omitted meta-analysis on the association of PSA persistence with OM due to an insufficient number of studies. PSA persistence was associated with disease recurrence in a sub-group of patients with pathological nodal involvement (HR: 5.90, 95% CI: 3.76-9.24). Understanding detection of PSA persistence at 4-8 weeks after RP might be useful for patient counseling, follow-up scheduling, and clinical decision-making regarding adjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.